drugset / Trial / NCT04446507
A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function
Non-randomizedParallel-groupOpen-labelOther
Summary
This will be a Phase 1, Open-label Study of Participants with Normal Renal Function and Participants with Sever Renal Impairment.
Timeline
- Start
- 2020-07-27
- Primary completion
- 2024-05-28
- Completion
- 2024-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saroglitazar | Small molecule | 2 mg | — |
| Subject | Saroglitazar | Small molecule | 4 mg | — |